CalciMedica, Inc. (CALC)
NASDAQ: CALC · Real-Time Price · USD
0.577
-0.014 (-2.30%)
At close: Apr 28, 2026, 4:00 PM EDT
0.572
-0.005 (-0.78%)
After-hours: Apr 28, 2026, 7:58 PM EDT
CalciMedica Employees
CalciMedica had 16 employees as of December 31, 2025. The number of employees increased by 2 or 14.29% compared to the previous year.
Employees
16
Change (1Y)
2
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$1,847,625
Market Cap
9.08M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16 | 2 | 14.29% |
| Dec 31, 2024 | 14 | 2 | 16.67% |
| Dec 31, 2021 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| BioLineRx | 24 |
| Bolt Biotherapeutics | 23 |
| Genprex | 13 |
| Kiora Pharmaceuticals | 13 |
| NuCana | 12 |
| Aprea Therapeutics | 8 |
| Enveric Biosciences | 6 |
CALC News
- 2 months ago - CalciMedica Reports 2025 Financial Results and Provides Clinical Updates - PRNewsWire
- 3 months ago - CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis - Benzinga
- 3 months ago - CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation - PRNewsWire
- 5 months ago - CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates - PRNewsWire
- 5 months ago - CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension - PRNewsWire
- 6 months ago - CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025 - PRNewsWire
- 7 months ago - CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™ - PRNewsWire
- 8 months ago - CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire